<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03592264</url>
  </required_header>
  <id_info>
    <org_study_id>OBI-3424-001</org_study_id>
    <nct_id>NCT03592264</nct_id>
  </id_info>
  <brief_title>This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer</brief_title>
  <official_title>A Phase I/II Study of OBI-3424 in Subjects With Solid Tumors, Hepatocellular Carcinoma and Castrate-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OBI Pharma, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OBI Pharma, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D,
      PK, and preliminary efficacy of OBI-3424 administered as a single agent in patients with
      solid tumors, hepatocellular carcinomas (HCC), and castrate-resistant prostate cancer (CRPC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events (AEs)</measure>
    <time_frame>Adverse events will be noted as it occurs. Timeframe for measure begins after first administration of study drug until 30 days after last dose of study drug. Study duration defined as up to 2 years.</time_frame>
    <description>Adverse events will be graded according to the Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess safety changes in electrocardiogram (ECG)</measure>
    <time_frame>Day 1 Cycles 1 and 2 (each cycle is 21 days)</time_frame>
    <description>Resting 12-lead ECGs will be obtained from all subjects' pre-OBI-3424 infusion and within 15 minutes post-OBI-3424 infusion in order to assess any impact OBI-3424 may have on the QT interval as assessed by the Fridericia's Correction Formula (QTcF).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess safety changes of body weight.</measure>
    <time_frame>Day 1 of each cycle (there are 34 cycles; 21 days for each cycle)</time_frame>
    <description>If during treatment a subject's body weight changes by &gt;10%, the dose should be adjusted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicities (DLTs)</measure>
    <time_frame>Throughout Cycle 1 (21 days for each cycle)</time_frame>
    <description>A DLT is defined as the occurrence of Grade 3/4 adverse events within the first cycle (the first 21 days) of treatment that are considered by the investigator to be at least possibly related to OBI-3424.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Define the Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>Days 1 and 8 of each cycle (all 34 cycles and there are 21 days for each cycle)</time_frame>
    <description>Determination of the MTD, based on the frequently of DLTs observed in Cycle 1 in subjects recruited to the Dose Escalation Phase.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) - Time to maximum concentration (Tmax)</measure>
    <time_frame>Days 1 and 8 of Cycle 1 (first cycle of 34 cycles and there are 21 days for each cycle)</time_frame>
    <description>Tmax of OBI-3424 and OBI-2660 will be computed for each subject where possible.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK - Maximum peak plasma concentration (Cmax)</measure>
    <time_frame>Days 1 and 8 of Cycle 1 (first cycle of 34 cycles and there are 21 days for each cycle)</time_frame>
    <description>Cmax of OBI-3424 and OBI-2660 will be computed for each subject where possible.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK - The magnitude of the slope of the linear regression of the log concentration vs. time profile during the terminal phase (Kel)</measure>
    <time_frame>Days 1 and 8 of Cycle 1 (first cycle of 34 cycles and there are 21 days for each cycle)</time_frame>
    <description>Kel of OBI-3424 and OBI-2660 will be computed for each subject where possible.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK - Half-life (T1/2)</measure>
    <time_frame>Days 1 and 8 of Cycle 1 (first cycle of 34 cycles and there are 21 days for each cycle)</time_frame>
    <description>T1/2 computed as ln (2)/Kel of OBI-3424 and OBI-2660 will be computed for each subject where possible.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK - Area under the concentration-time curve (AUClast)</measure>
    <time_frame>Days 1 and 8 of Cycle 1 (Cycle 1 is 21 days)</time_frame>
    <description>AUClast from Hour 0 through the last quantifiable concentration time (LQCT), where LQCT is the time at which the last sample with a quantifiable concentration was drawn</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Hepatocellular Carcinomas (HCC)</condition>
  <condition>Castrate-resistant Prostate Cancer (CRPC)</condition>
  <arm_group>
    <arm_group_label>Dose escalation phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OBI-3424 (1.0 mg/m^2 to 24.0 mg/m^2) will be administered by IV infusion on Days 1 and 8 of each 21-day cycle to determine the MTD and RP2D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort expansion phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once the MTD and RP2D is determined then OBI-3424 (dosage TBD) will be administered by IV infusion on Days 1 and 8 of each 21-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OBI-3424</intervention_name>
    <description>liquid formulation for Intravenous infusion</description>
    <arm_group_label>Cohort expansion phase</arm_group_label>
    <arm_group_label>Dose escalation phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. At least 18 years of age

          2. Ability to understand the purposes and risks of the study and has signed a written
             informed consent form approved by the investigator's Institutional Review Board
             (IRB)/Independent Ethics Committee (IEC)

          3. Recovered from toxicities of prior therapy to Grade 0 or 1

          4. Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST version
             1.1) criteria or for rising prostate specific antigen (PSA) according to the Prostate
             Cancer Working Group 3 (PCWG3) criteria for subjects with CRPC

          5. Available tissue (including archival tissue) for retrospective AKR1C3 expression
             analysis (except for subjects with CRPC where this is not a requirement for
             inclusion). Patients must agree to a fresh tumor biopsy in case an archival sample is
             not available.

          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          7. Cardiac QTcF interval ≤ 450msec for males and ≤470 msec for females

          8. Acceptable liver function:

               1. Bilirubin ≤1.5 × institutional ULN

               2. AST and ALT ≤3.0 × ULN, or ≤5.0 × ULN for subjects with liver involvement

          9. Acceptable renal function:

             a. Creatinine clearance &gt;30 mL/min according to the Cockcroft-Gault formula

         10. Acceptable hematologic status (without hematologic support, other than red blood cell
             transfusion):

               1. ANC ≥1500 cells/μL

               2. Platelet count ≥100,000/μL

               3. Hemoglobin ≥9.0 g/dL

         11. Females of childbearing potential must not have had unprotected sexual intercourse
             within 30 days before study entry and must agree to use a highly effective method of
             contraception (e.g., total abstinence, an intrauterine device, a double-barrier method
             [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral
             contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout
             the entire study period and for 30 days after study drug discontinuation.

        Exclusion Criteria:

          1. Prior radiotherapy to more than 25% of the bone marrow

          2. Symptomatic brain metastases, unless previously treated and well controlled for at
             least 4 weeks after central nervous system (CNS)-directed treatment as ascertained by
             clinical examination and brain imaging (magnetic resonance imaging [MRI] or computed
             tomography [CT]) during the Screening Period. Patients with known leptomeningeal
             disease are excluded.

          3. Previously treated malignancies, except for adequately treated non-melanoma skin
             cancer, in situ cancer, or other cancers whose natural history or treatment does not
             have the potential to interfere with the safety or efficacy assessment of the current
             study

          4. Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without
             complete recovery

          5. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic
             therapy

          6. Treatment with radiation therapy, surgery, chemotherapy, targeted therapies or
             hormones within 3 weeks prior to study entry (6 weeks for nitrosoureas or mitomycin C)

          7. Concomitant use of strong CYP3A4 inhibitors/inducers

          8. Subjects who participated in an investigational drug or device study within 28 days
             prior to study entry

          9. Subjects with known HIV infection, unless CD4 ≥500 cells/μL and HIV RNA below the
             limit of detection on stable doses of antiretroviral therapy

         10. Subjects with chronic HBV infection, unless Screening viral load &lt;100 IU/mL on stable
             doses of antiviral therapy. Note: Subjects with chronic HCV infection are allowed to
             enroll in the study but do not have a defined maximum viral load requirement for study
             entry.

         11. Females who are pregnant or breast-feeding

         12. Concomitant disease or condition that could interfere with the conduct of the study,
             or that would, in the opinion of the investigator, pose an unacceptable risk to the
             subject in this study

         13. Unwillingness or inability to comply with the study protocol for any reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Apostolia Tsimberidou, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liz Yu</last_name>
    <phone>+886-2-27866589</phone>
    <phone_ext>208</phone_ext>
    <email>lyu@obipharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 21, 2018</study_first_submitted>
  <study_first_submitted_qc>July 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

